Research Article

4-Octyl Itaconate Prevents Free Fatty Acid-Induced Lipid Metabolism Disorder through Activating Nrf2-AMPK Signaling Pathway in Hepatocytes

Xu Chu,1,2 Longlong Li,1,2 Weiyuan Yan,1,2 and Haitian Ma1,2

1Key Laboratory of Animal Physiology and Biochemistry, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, China
2MOE Joint International Research Laboratory of Animal Health and Food Safety, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, China

Correspondence should be addressed to Haitian Ma; mahaitian@njau.edu.cn

Received 21 October 2021; Revised 10 January 2022; Accepted 5 February 2022; Published 18 February 2022

Academic Editor: Mateusz Maciejczyk

Copyright © 2022 Xu Chu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Nonalcoholic fatty liver disease (NAFLD), characterized with oxidative stress and hepatic steatosis, is a serious threat to human health. As a specific activator of nuclear factor E2-related factor 2 (Nrf2), the 4-octyl itaconate (4-OI) has the beneficial effects in antioxidant and anti-inflammation; however, whether 4-OI can alleviate hepatic steatosis and its mechanism is still unknown. The present study was aimed at investigating the protective effects of 4-OI on free fatty acid- (FFA-) induced lipid metabolism disorder and its potential molecular mechanism in hepatocytes. The results showed that 4-OI treatment markedly alleviated FFA-induced oxidative stress and excessive lipid accumulation in hepatocytes. Mechanistically, 4-OI significantly suppressed the overproduction of reactive oxygen species (ROS) through activation of Nrf2; the downregulation of ROS level induced a downregulation of AMP-dependent protein kinase (AMPK) phosphorylation level which finally ameliorated excessive lipid accumulation in FFA-stimulated hepatocytes. In general, our data demonstrated that 4-OI relieves the oxidative stress and lipid metabolism disorder in FFA-stimulated hepatocytes; and these beneficial effects were achieved by activating the Nrf2-AMPK signaling pathway. These data not only expand the new biological function of 4-OI but also provide a theoretical basis for 4-OI to protect against lipid metabolism disorders and related diseases, such as NAFLD.

1. Introduction

Nonalcoholic fatty liver disease (NAFLD) is mainly caused by intemperate diet and irregular lifestyle, which seriously threatens human health [1]. In recent years, the prevalence of NAFLD has generally increased in the world [2] and has become a precursor of liver fibrosis, liver cirrhosis, and even liver cancer [3, 4]. Previous studies found that NAFLD not only associates with the increase of liver-related morbidity but also affects the occurrence of many metabolic diseases [5, 6]. The pathogenesis of NAFLD is summarized as "multi-hit hypothesis," including the excessive liver fat deposition that causes oxidative stress and inflammatory response, which finally exacerbates hepatic steatosis [7]. Currently, there is no effective strategy for the prevention of NAFLD; most bioactive substance or metabolic intermediates exhibit a multitudinous potential effects; employing it to reduce fat accumulation, oxidative stress, or inflammatory response may be an effective strategy for alleviating NAFLD and other metabolic diseases.

Oxidative stress is caused by the imbalance of the redox system in the pathological state of the body [8]. Nuclear factor E2-related factor 2 (Nrf2) has been proved to mediate the antioxidant factor expression, which is the main pathway in regulating oxidative stress and electrophilic stress [9]. Under stress conditions, Nrf2 is combined with an antioxidant response element to initiate the transcription of related genes and improve the antioxidant capacity, which then reduces the production of reactive oxygen species (ROS) in the body [10, 11]. It is reported that oxidative stress leads
to high levels of ROS production; and the activation of AMPK-dependent protein kinase (AMPK) is affected by ROS level [12–14]. As an important energy sensor and regulator, AMPK plays an important role in regulating lipid deposition [15, 16]; thus, activated AMPK maybe as a potential target in preventing NAFLD and related metabolic diseases.

Itaconic acid is generated from the decarboxylation of tricarboxylic acid cycle (TCA) intermediate cis-aconitic acid by the catalyzing of immune response gene 1 in macrophages [17]; and it has protective effects on oxidative stress and inflammatory response [18, 19]. Previous study have shown that itaconic acid can directly alkylate cysteine residue on Kelch-like ECH-associated protein 1 (Keap1), thereby activating Nrf2 to exert antioxidant and anti-inflammatory effects [20]. At present, research on itaconic acid has mainly focused on its immunomodulation, and it has been found that it has a notable anti-inflammatory effect on activated macrophages [21, 22]. As an unsaturated dicarboxylic acid, itaconic acid is difficult to penetrate cell membrane and is not suitable for a mechanism study. Thus, 4-octyl itaconate (4-OI), a cell-permeable itaconic acid derivative [23], is widely used in the corresponding molecular studies. It is reported that 4-OI exerts metabolic regulatory effects by affecting the activity of key enzymes in the TCA cycle [24]; and it can reduce the supply of energy substances by interfering with the glycolysis pathways, reducing energy consumption and fat deposition [25]. Moreover, 4-OI can also exert antioxidant effects by inhibiting ROS production in hepatocytes [25]. However, whether 4-OI can alleviate the oxidative stress and lipid metabolism disorder in hepatocytes is still unknown.

Therefore, the present study was aimed at verifying the protective effects and molecular mechanisms of 4-OI against free fat acid (FFA)-stimulated lipid metabolism disorder and oxidative stress in the BRL-3A and LO2 cells. We found that 4-OI significantly blocked the overproduction of ROS through activating Nrf2, leading to the activation of AMPK signaling, which then alleviated excessive lipid accumulation in FFA-stimulated hepatocytes. These findings not only reveal novel biological function of 4-OI but also provide a theoretical basis for its use as a nutritional supplement to protect against metabolism disorders and related diseases such as NAFLD.

2. Materials and Methods

2.1. Chemicals. 4-Octyl itaconate (4-OI), dimethyl sulfoxide (DMSO), methyl thiazolyl tetrazolium (MTT), penicillin-streptomycin, and trypsin were purchased from Sigma (St. Louis, MO, USA). RPMI 1640 was purchased from Gibco (Grand Island, NY, USA). The TRIzol reagent kit was purchased from Invitrogen (Carlsbad, CA, USA). Ex Taq DNA polymerase was purchased from TaKaRa Bio Inc. (Shiga, Japan), and SYBR Green PCR Master Mix was purchased from Roche (Basel, Switzerland). The assay kits of superoxide dismutase (SOD, #mbs237a), peroxidase (POD, #mbca502), catalase (CAT, #mbe12189), total antioxidant capacity (T-AOC, #a015a), malondialdehyde (MDA, #a00312), and triglyceride (TG) were obtained from Nanjing Jiancheng Institute of Biotechnology (Nanjing, China). BCA protein assay kit was purchased from Beyotime Institute of Biotechnology (Shanghai, China). Compound C, NAC, and ML385 were purchased from Beyotime Biotechnology Institute (Shanghai, China). The rabbit anti-Nrf2 (A0647), Keap1 (A17062), AMPK (A1009), p-AMPK (AP0637), ACC1 (AG16452), p-ACC1 (A1346), and SREBP-1 (AB133125) antibodies were purchased from ABclonal Technology Co., Ltd. (Wuhan, China); and goat anti-rabbit IgG (H+L) FITC (BL033A) antibody was obtained from Biosharp (Hefei, China).

2.2. Cell Culture and Treatment. Human liver LO2 cells (Hongsheng Biological Technology Co., Ltd., Nanjing, China) and rat liver BRL-3A cells (ATCC, Manassas, VA) were, respectively, cultured in RPMI 1640 and DMEM with 10% fetal bovine serum, 100 U/ml penicillin, and 100 μg/ml streptomycin; and the cells were maintained in a humidified atmosphere of 5% CO2, air at 37°C. The LO2 cells and BRL-3A cells were pretreated with 4-OI for 4 h and then treated with 0.75 mM FFA (oleic acid: palmitic acid = 2:1) for another 24 h.

2.3. Cell Viability Assay. The LO2 cells and BRL-3A cells were seeded in 96-well plates (5×103 cells/well) and then treated with 0, 12.5, 25, 50, or 100 μM 4-OI for 4 h. Then, 10 μl MTT (5 mg/ml in PBS) was added to each well and incubated at 37°C for 4 h; after that, the culture supernatant was removed, and 150 μl DMSO was added to dissolve crystals. The absorbance was measured at 490 nm using a model 550 Microplate Reader (Bio-Rad, California, USA).

2.4. TG Content Analysis and Lipid Droplets Accumulation. The LO2 cells and BRL-3A cells were seeded into 6-well plates (1×106 cells/well). BRL-3A cells were pretreated with or without 25, 50, and 100 μM 4-OI for 4 h, and the LO2 cells were pretreated with or without 50 μM 4-OI for 4 h; then, all cells were cultured with or without 0.75 mM FFA for another 24 h. The cells were collected, and TG contents were measured using the commercial kit, and the data were normalized to the protein concentration as determined by BCA protein assay kit following the manufacturers.

For the analysis of lipid droplet accumulation, Nile red staining is used in this study. Briefly, the cells were pretreated with or without 50 μM 4-OI for 4 h and then cultured with or without 0.75 mM FFA for another 24 h. After that, the cells were stained with Nile Red staining solution at 37°C for 10 min and washed with PBS, and then, the cells were photographed using a Zeiss 710 Laser Scanning confocal microscope (Zeiss, Germany).

2.5. Antioxidant Capacity Analysis. The LO2 and BRL-3A cells were grown in 6-well plates (1×106 cells/well). The BRL-3A cells were pretreated with or without 25, 50, and 100 μM 4-OI for 4 h, and the LO2 cells were pretreated with or without 50 μM 4-OI for 4 h; then, all cells were cultured with or without 0.75 mM FFA for another 24 h. The cells were stained with Nile Red staining solution at 37°C for 10 min and washed with PBS, and then, the cells were photographed using a Zeiss 710 Laser Scanning confocal microscope (Zeiss, Germany).
were washed and collected, disrupted ultrasonically in ice, and centrifuged at 2500 rpm for 10 min at 4°C. The activity of T-AOC, SOD, CAT, POD, and the content of MDA was determined following the commercial kit manufacturers, and the data were normalized with protein content that was determined using a BCA assay kit according to the manufactures.

2.6. Reactive Oxygen Species (ROS) and Mitochondrial ROS (mROS) Analysis. Intracellular generation of ROS and mROS was detected with the probes of 2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA) and MitoSOX Red (Thermo, Waltham, MA, USA). Briefly, the L02 cells and BRL-3A cells were pretreated with or without 50 μM 4-OI for 4 h and then cultured with or without 0.75 mM FFA for another 24 h. Subsequently, the culture supernatant was removed, and the cells were treated with 10 μM DCFH-DA probe or 5 μM MitoSOX Red probe for 30 min in the dark. After that, the cells were washed with PBS and photographed using a Zeiss 710 Laser Scanning confocal microscope (Zeiss, Germany).

2.7. Measurement of Mitochondrial Membrane Potential. The mitochondrial membrane potential (MMP) was measured using JC-1 probe (Beyotime Institute of Biotechnology, Shanghai, China). In brief, the cells were seeded into 12-well plates (1 × 10^4 cells/well) and preincubated with or without Nrf2 inhibitor 10 μM ML385 for 12 h and then treated with or without 50 μM 4-OI for 4 h; after that, the cells were treated with 0.75 mM FFA for another 24 h. After the experiment, the cells were incubated with JC-1 probe for 30 min at 37°C in the dark and then washed with JC-1 washing buffer; the samples were imaged using a Zeiss 710 Laser Scanning confocal microscope (Zeiss, Germany).

2.8. Real-Time Quantitative PCR Analysis. The total RNA was extracted and determined using the TRIZOL reagent kit as previously described [26]. Briefly, total RNA was reverse transcribed into cDNA using the Superscript II kit (Promega, USA) according to the manufacturers. The mRNA level was quantified by real-time quantitative PCR using a SYBR green PCR kit (Roche, Switzerland). All results were analyzed in duplicate using the IQ5 Sequence Detection System (Bio-Rad, California, USA). The 2ΔΔCT method was used to calculate the fold change in the mRNA levels. The forward and reverse primers for sterol-regulatory element binding proteins-1c (SREBP-1c), fatty acid synthase (FAS), carnitine palmitoyl transferase-1 (CPT-1), peroxidase proliferation-activated receptor alpha (PPARα), heme oxygenase-1 (HO-1), NAD(P)H: quinone oxidoreductase 1 (NQO1), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) are displayed in Table 1. The GAPDH was used as the standard.

2.9. Western Blot Analysis. Total protein from the was extracted using NP40 lysis buffer and quantified by BCA assay following introduction of the manufacturers and then separated using 10% SDS-PAGE gels. Then, the extracted protein were transferred onto PVDF members and then blocked with 5% nonfat milk for 2 h. The membranes were incubated overnight at 4°C with rabbit antibodies against the Nrf2, Keap1, AMPK, p-AMPK, ACC1, p-ACC1, and SREBP-1. After washing, the membranes were incubated with secondary antibody for another 2 h at room temperature. The ECL enhanced chemiluminescence was used as a detecting agent, and the protein abundance was quantified by the ImageJ software.

2.10. Statistical Analysis. The GraphPad Prism 5 software was performed to analysis the data, and the one-way ANOVA and Student-Newman-Keuls test were used for comparing the significant differences among different treatments. All of the results were obtained from at least three independent experiments.

### Table 1: Sequences of target genes and GAPDH primers.

| Target gene | Primers sequence          |
|-------------|---------------------------|
| SREBP-1c    | F 5′-GTGTATGTCCTGCGCATGCT-3′ |
|             | R 5′-CTCCCAAAGTGCTGACAGA-3′ |
| FAS         | F 5′-AGGCCCTCATAGACCTGCTG-3′ |
|             | R 5′-GGGAGATGAGGGGAGTTCCCT-3′ |
| CPT-1       | F 5′-ATCAATCGGACTCTGGAAG-3′ |
|             | R 5′-CAGCGGAGCTGACATGGT-3′ |
| PPARα       | F 5′-GGCCAGCAAATAGTGCAAGA-3′ |
|             | R 5′-AACGACCTCCTGGAAGGAGC-3′ |
| HO-1        | F 5′-CGCAGACCTTGTGATATCCAGT-3′ |
| NQO1        | R 5′-GGTCCTTTGGTCATACGGAG-3′ |
| GAPDH       | F 5′-CCTGCCACCCAACACTGTTAG-3′ |
|             | F 5′-CATCTTGTGGGTGCGAGTA-3′ |

Figure 1, no significant differences were observed on the cell viability in the LO2 cells and BRL-3A cells treated with 12.5-100 μM 4-OI, which implied that the doses of 4-OI used in this experiment will not cause obvious cell toxicity.

We found that the intracellular TG content was significantly increased in FFA-induced cells, while 4-OI treatment effectively reduced the TG content than the FFA-stimulated group in the LO2 and BRL-3A cells (Figures 2(a) and 2(b)). To further certify these results, the Nile Red staining was used to evaluate the lipid droplets accumulation, and the results showed that lipid droplet accumulation was obviously increased in the FFA-induced LO2 cells and BRL-3A cells when compared to the control group, while 4-OI treatment effectively attenuated the lipid droplet accumulation in hepatocytes (Figure 2(c)). These results illustrated that 4-OI alleviated the lipid accumulation in the FFA-stimulated hepatocytes.
**Figure 1:** Effects of 4-OI on cell viability in the LO2 and BRL-3A cells. The LO2 cells and BRL-3A cells were cultured with 0, 12.5, 25, 50, or 100 μM 4-octyl itaconate (4-OI) for 4 h. Viability of the LO2 cells (a) or BRL-3A cells (b) under treated with different doses of 4-OI. Data are presented as the means ± SEM.

**Figure 2:** 4-OI alleviates FFA-induced lipid accumulation in hepatocytes. The BRL-3A cells were pretreated with or without 25, 50, and 100 μM 4-octyl itaconate (4-OI) for 4 h; and the LO2 cells were pretreated with or without 50 μM 4-OI for 4 h; then, all cells were treated with or without 0.75 mM free fat acid (FFA) for another 24 h. (a) Triglyceride (TG) content in the BRL-3A cells. (b) TG content in the LO2 cells. (c) Representative pictures of Nile red staining in the BRL-3A cells (A–C) and LO2 cells (D–F). Data are presented as the means ± SEM. *P < 0.05 and **P < 0.01, compared to the NC group. #P < 0.05 and ##P < 0.01, compared to the FFA group.
3.2. 4-OI Relieves Lipid Accumulation through Activated AMPK Pathway in Hepatocytes. It is reported that AMPK plays a crucial role in lipid metabolism [27]. In this study, we found that 4-OI treatment significantly increased the AMPK and ACC1 phosphorylation protein level; but the SREBP-1 protein level was significantly decreased in the FFA-stimulated LO2 cells pretreated with 4-OI (Figure 3(a)). Meanwhile, 4-OI treatment also enhanced the phosphorylation protein level of AMPK and ACC1 and reduced SREBP-1 protein level in the FFA-stimulated BRL-3A cells (Figure 3(b)).

To further verify the actions of 4-OI regulating lipid metabolism whether associated with the activating of AMPK, the hepatocytes were preincubated with 10 μM AMPK inhibitor compound C to block the phosphorylation of AMPK. The results showed that 4-OI induced the upregulation of phosphorylation of AMPK and ACC1 protein level and the downregulation of SREBP-1 protein level completely reversed in the FFA-stimulated LO2 cells and BRL-3A cells pretreated with compound C (Figures 3(c) and 3(d)). Meanwhile, the RT-qPCR assay also showed that 4-OI treatment significantly decreased the upregulation of SREBP-1c and FAS mRNA level and the downregulation of CPT-1 and PPARα mRNA levels in the FFA-stimulated LO2 cells, and these actions of 4-OI were also obviously reversed in the FFA-stimulated LO2 cells pretreated with compound C (Figure 3(e)). Importantly, we found that the deceasing effect of TG content induced by 4-OI treatment was disappeared in the FFA-stimulated LO2 cells pretreated with compound C (Figure 3(f)). These data implied that 4-OI relieves lipid accumulation via activating AMPK signaling pathway in hepatocytes.

3.3. 4-OI Activates AMPK Pathway by Preventing the Overproduction of ROS in Hepatocytes. The increase of intracellular ROS production was significantly blocked in the FFA-stimulated hepatocytes treated with 4-OI (Figure 4(a)). A series of studies have shown that the AMPK activation is related to ROS levels [12]. To verify the activation of AMPK induced by 4-OI whether it is related to the inhibition of ROS overproduction in the FFA-stimulated hepatocytes, we next detected the AMPK phosphorylation level in hepatocytes pretreated with 5 μM ROS scavenger NAC. The results showed that NAC alone treatment obviously increased the AMPK phosphorylation protein level and decreased the TG content in the FFA-stimulated LO2 cells (Figures 4(b) and 4(c)). However, NAC and 4-OI treatments synergistically significantly decreased the TG content (Figure 4(c)) and SREBP-1 protein level (Figures 4(d) and 4(e)) and significantly enhanced the phosphorylation of AMPK and ACC1 protein level in the FFA-induced LO2 cells or BRL-3A cells (Figures 4(d) and 4(e)). Taken together, these results indicated that 4-OI can activate AMPK signaling pathway by reducing intracellular ROS overproduction in hepatocytes.

3.4. 4-OI Relieves FFA-Induced Oxidative Stress by Activated Nrf2 in Hepatocytes. The oxidation and antioxidant systems of the body are usually in dynamic balance and maintain the normal life activities [8]; once this dynamic equilibrium is broken, it is easy to cause oxidative stress. As shown in Figures 5(a) and 5(b), FFA alone treatment caused a significant decrease in the activities of T-AOC, CAT, and POD, which was significantly reversed in the LO2 cells and BRL-3A cells treated with 4-OI. In addition, the MDA content significantly increased after FFA treatment, and the addition of 4-OI treatment significantly reduced MDA content in the presence or absence of FFA in the LO2 cells (Figure 5(c)).

It well known that the Nrf2 cascade is a classic antioxidant pathway. In order to further explore the mechanisms of 4-OI alleviating the accumulation of ROS, we subsequently analyzed the effect of 4-OI on the Nrf2 signaling pathway. Western blot analysis showed that 4-OI treatment significantly alleviated the FFA-induced downregulation of Nrf2 protein level and upregulation of Keap1 protein level in the LO2 cells and BRL-3A cells (Figures 5(d) and 5(e)). Consistently, 4-OI treatment significantly increased the mRNA levels of HO-1 and NQO1 in the presence or absence of FFA in the LO2 cells (Figure 5(f)). Therefore, these results indicated that 4-OI can protect against the FFA-induced oxidative stress through activation of Nrf2 signaling pathway.

3.5. 4-OI Activates AMPK Pathway via Nrf2-Mediated Inhibition on mROS Production. In order to further verify that 4-OI reduces FFA-induced ROS accumulation by activating the Nrf2 signaling pathway, subsequently, hepatocytes were preincubated with 10 μM Nrf2 inhibitor ML385. As shown in Figures 6(a) and 6(b), 4-OI induced the upregulation of Nrf2 protein level and the downregulation of Keap1 protein level markedly reversed in the FFA-stimulated LO2 cells and BRL-3A cells by pretreatment with ML385. Moreover, we found that the increase of nuclear Nrf2 protein level induced by 4-OI treatment obviously dispelled in the FFA-stimulated LO2 pretreatment with ML385 (Figure 6(a)). Mitochondrial membrane potential (MMP) and mitochondrial ROS (mROS) levels were measured by JC-1 and DCFH-DA fluorescent probe, the representative images showed that 4-OI treatment significantly attenuated the increase of mROS production and the decrease of MMP level in the FFA-stimulated LO2 cells and BRL-3A cells, and these effects was blocked in cells pretreatment with ML385 (Figures 6(c) and 6(d)). Importantly, we also found that ML385 inhibited the increase of phosphorylation AMPK protein level induced by 4-OI treatment in the FFA-stimulated LO2 cells (Figure 6(f)). Meanwhile, the reduced action on TG content induced by 4-OI treatment was also completely reversed in the FFA-stimulated LO2 cells pretreated with ML385 (Figure 6(e)). These results demonstrated that 4-OI inhibits the overproduction of mROS through the activated Nrf2, which subsequently activates AMPK signal pathway to inhibit the lipid accumulation in the FFA-stimulated hepatocytes.

4. Discussion

Numerous studies have shown that excessive intake of free fatty acids can lead to abnormal lipid deposition in hepatocytes and then lead to oxidative stress and inflammatory
Figure 3: Continued.
response, which may exacerbate liver steatosis [28–31]. Therefore, alleviating abnormal lipid deposition and oxidative stress becomes an effective strategy for the prevention of NAFLD. Previous study had found that treatment with 4-OI can protect against oxidative stress and inflammatory response in vivo and in vitro [17]. However, whether 4-OI can alleviate hepatic steatosis and oxidative stress and its mechanism is still unknown. In this study, we demonstrated that 4-OI alleviates FFA-induced lipid metabolism disorder in hepatocytes by activating AMPK signaling pathway; importantly, the activation of AMPK pathway was achieved via Nrf2-mediated inhibition of mROS production in the FFA-stimulated hepatocytes (Figure 7). These results provided a new insight for 4-OI used as a lipid-lowering regulator to protect lipid metabolism disorders and related diseases.

Under normal physiological conditions, lipid synthesis and lipolysis are in homeostasis [32]; and once this dynamic is broken due to increased synthesis and/or weakened decomposition of lipids, it may lead to excessive lipid accumulation [33, 34]. The lipid droplet accumulation and TG content in the cells are important parameters for assessing lipid deposition [35]. In the present study, we found that 4-OI treatment significantly reduced the lipid droplet accumulation and TG content in the FFA-stimulated LO2 cells and BRL-3A cells, which implied that 4-OI can alleviate lipid accumulation in the FFA-stimulated hepatocytes. As a metabolic regulatory factor, activated AMPK can reduce lipid deposition through inhibiting lipid synthesis-related factors expression and enhancing lipolysis-related factors expression [36]. In this study, 4-OI significantly reversed the reduction of AMPK and ACC1 phosphorylation levels and the increase of SREBP-1 protein levels in hepatocytes induced by FFA-stimulated. As a key downstream target factor of AMPK, ACC1 is a rate-limiting enzyme in the fatty acid synthesis pathway [37], and its activity is inhibited by its phosphorylation [38]. In order to further clarify whether AMPK plays a crucial role in 4-OI mediated lipid lowering in hepatocytes, the AMPK inhibitor compound C was used to block the AMPK phosphorylation. We observed that the activation of AMPK signaling pathway induced by 4-OI treatment was observably reversed in the FFA-stimulated hepatocytes pretreated with compound C. Meanwhile, compound C pretreatment also blocked the effects of 4-OI on reducing the mRNA or protein levels of SREBP-1c and FAS and promoting the PPARα and CPT-1 mRNA levels in the FFA-stimulated hepatocytes. SREBP is an important nuclear transcription factor that regulates the genes expression related to lipid synthesis [39, 40]; as one of the subtypes, SREBP-1c is mainly responsible for activating the expression of lipid synthesis genes [41]. In addition, acetyl-CoA can be catalyzed by ACC1 to generate malonic acid monacetyl CoA, which finally is catalyzed by FAS to produce fatty acids [42]. Taken together, these data indicated that 4-OI alleviates the lipid deposition by activation of AMPK signaling pathway in the FFA-stimulated hepatocytes.

Mitochondria are the main organelle that generates endogenous ROS [43]. In mitochondria, electrons flow to complex IV in an orderly manner along the electron transport chain and react with oxygen-containing substances at several electron transfer points to produce ROS [44]. Excessive lipid accumulation can abate the mitochondrial respiratory chain enzymes activity, change mitochondrial membrane permeability, and induce excessive production...
**Figure 4:** 4-OI activates AMPK signaling pathway by reducing ROS production. The LO2 cells and BRL-3A cells were pretreated with/without reactive oxygen species (ROS) scavenger NAC (5 μM) for 1 h, then cultured with or without 50 μM 4-octyl itaconate (4-OI) for 4 h, and then added with/without 0.75 mM free fat acid (FFA) for another 24 h. (a) Representative pictures of ROS levels in the LO2 cells (A–C) and BRL-3A cells (D–F). (b) Immunoblotting and statistical analysis of p-AMP-dependent protein kinase (AMPK) and AMPK in the LO2 cells. Data are presented as the means ± SEM. **P < 0.01, compared to the NC group. ##P < 0.01, compared to the FFA group. (c) TG content in the LO2 cells. (d) Immunoblotting and statistical analysis of p-AMPK, AMPK, p-ACC1 (acetyl-CoA carboxylase 1), ACC1, and sterol-regulatory element binding proteins-1 (SREBP-1) in the LO2 cells pretreated with ROS scavenger NAC. (e) Immunoblotting and statistical analysis of p-AMPK, AMPK, p-ACC1, ACC1, and SREBP-1 in the BRL-3A cells pretreated with ROS scavenger NAC. (c–e) Data are presented as the means ± SEM. *P < 0.05 and **P < 0.01, comparison between the indicated groups.
Figure 5: Continued.
of ROS [45, 46]. The homeostasis between the production and clearance of ROS is the basis for maintaining normal cell functions [47]. In present study, we found that 4-OI reduced the ROS overproduction in the FFA-stimulated hepatocytes. As a signal molecule regulating biochemical pathways, the excessive production of ROS will destroy the body’s oxidation defense system [48]. Our also found that FFA induced an increase of MDA content, while 4-OI treatment significantly reduced MDA content and increased the total antioxidant capacity in the FFA-stimulated hepatocytes. MDA level is a marker to measure the effect of lipid peroxidation, and the decrease of MDA content is also an indicator to improve antioxidant performance [49]. Moreover, we found that FFA induced the inhibition of the activities of SOD, CAT, and POD alleviated in hepatocytes treated with 4-OI. These results implied that 4-OI improved the antioxidant capacity and attenuated the ROS accumulation in the FFA-stimulated hepatocytes.

The damage is caused by oxidative stress involved in all aspects of metabolism [50]. As a classic antioxidant pathway, the Keap1-Nrf2 system is the major regulatory pathway for cytoprotective gene expression against oxidative stresses [51, 52]. In this study, 4-OI treatment obviously increased the expression of Nrf2 protein and its downstream genes. These results are consistent with the previous reported by Mills et al. [17]. Moreover, our results found that the increase of Nrf2 protein level and decrease of Keap1 protein level induced by 4-OI treatment were reversed in cells pretreated with Nrf2 inhibitor ML385. It has been reported that 4-OI acts as an activator of Nrf2 to alkylate cysteine residues on Keap1 and break the connection between Keap1 and Nrf2, which finally results the accumulation of Nrf2 in nuclear [17, 20]. In addition, our results showed that 4-OI ameliorated the decrease in mitochondrial membrane potential caused by overproduction of ROS in the FFA-stimulated hepatocytes. Thus, we speculate that 4-OI can improve the mitochondrial function through reducing ROS accumulation in the FFA-stimulated hepatocytes. Zorov et al. reported that high level of ROS can disrupt the normal function of mitochondria and produce more ROS [53, 54]. Meanwhile, mitochondrial membrane potential is the result of mitochondrial oxidative phosphorylation [54] and the basis of mitochondrial ATP production [55]. These results implied that 4-OI relieves oxidative damage by activating the Nrf2 signaling pathway that maintains the mitochondrial membrane potential and reduces the excessive production of mROS in the FFA-stimulated hepatocytes.

It is remarkable that excessive production of ROS induced by mitochondrial dysfunction can also lead to lipid metabolism disorders [56]. Therefore, we used ROS scavenger NAC to detect the AMPK signaling pathway in the hepatocytes. We observed that NAC alone treatment significantly alleviated the reduction of AMPK and ACC1 phosphorylation in the FFA-induced hepatocytes. Meanwhile, we used Nrf2 inhibitor ML385 to investigate the effect of Nrf2 on the activation of AMPK pathway. Interestingly, we found that ML385 significantly reversed the increase of AMPK phosphorylation level induced by 4-OI treatment in the FFA-stimulated hepatocytes. Meanwhile, the decreasing effect of 4-OI on TG content was also completely reversed in the FFA-stimulated hepatocytes pretreatment with ML385. These results demonstrated that 4-OI treatment activated AMPK pathway via the Nrf2-mediated inhibition on mROS production, which subsequently inhibited the lipid accumulation in the FFA-stimulated hepatocytes. Although we have provided in vivo evidence to demonstrate the role of 4-OI in regulating oxidative stress and lipid metabolism disorders, the specific mechanism deserves further study in combination with animal models. In addition, itaconate alkylates cysteine residues in proteins, including GAPDH, LDHA, and SDH except of Keap1, and these modifications inhibit glycolysis and TCA cycle, which are
Figure 6: Continued.
Figure 6: 4-OI indirectly activates AMPK via activating the Nrf2 signaling pathway. The LO2 cells and BRL-3A cells were preincubated with/without Nrf2 inhibitor ML385 (10 μM) for 12 h and then cultured with or without 50 μM 4-octyl itaconate (4-OI) for 4 h, and then added with/without 0.75 mM free fat acid (FFA) for another 24 h. (a) Immunoblotting and statistical analysis of nuclear factor E2-related factor 2 (Nrf2), Kelch-like ECH-associated protein 1 (Keap1), and nuclear Nrf2 in the LO2 cells pretreated with Nrf2 inhibitor ML385. (b) Immunoblotting and statistical analysis of Nrf2 and Keap1 in the BRL-3A cells pretreated with Nrf2 inhibitor ML385. (c) Representative pictures of mitochondrial membrane potential in the LO2 cells (A) and BRL-3A cells (B) determined by fluorescence microscopy. (d) Representative pictures of mitochondrial reactive oxygen species (mROS) level in the LO2 cells (A–D) and BRL-3A cells (E–H) determined by fluorescence microscopy. (e) Triglyceride (TG) content in the LO2 cells. (f) Immunoblotting and statistical analysis of p-AMP-dependent protein kinase (p-AMPK) and AMPK in the LO2 cells pretreated with Nrf2 inhibitor ML385. Data are presented as the means ± SEM. **P < 0.01, comparison between the indicated groups.

Figure 7: Schematic illustration of the mechanism of 4-OI alleviating lipid metabolism disorders by activating the Nrf2-AMPK signaling pathway. 4-Octyl itaconate (4-OI) enhances the antioxidant function through activating the nuclear factor E2-related factor 2 (Nrf2), which leads to the increase of mitochondrial membrane potential (MMP) and inhibition of the reactive oxygen species (ROS) overproduction in free fat acid- (FFA-) stimulated hepatocytes. Meanwhile, the downregulation of ROS level induces an increase of AMP-dependent protein kinase (AMPK) phosphorylation level, which alleviates the lipid deposition in free fat acid- (FFA-) stimulated hepatocytes. In conclusion, 4-OI relieves the oxidative stress and lipid metabolism disorder by activating the Nrf2-AMPK signaling pathway in FFA-stimulated hepatocytes.
important for the supply of cytosolic acetyl-CoA for fatty acid synthesis. Whether the regulation of lipid metabolism by 4-OI is also affected by glucose metabolism requires further research to explore this process in more detail.

5. Conclusion

Our data demonstrated that 4-OI enhances the antioxidant function through activating the Nrf2, which leads to the increase of MMP and inhibition of the ROS overproduction in the FFA-stimulated hepatocytes. Meanwhile, the down-regulation of ROS level induces an increase of AMPK phosphorylation level, which alleviates the lipid deposition in the FFA-stimulated hepatocytes. In conclusion, our findings indicated that 4-OI relieves the oxidative stress and lipid metabolism disorder by activating the Nrf2-AMPK signaling pathway in the FFA-stimulated hepatocytes. These data provide a theoretical basis for 4-OI as a nutritional supplement in the prevention and treatment of metabolism disorders and related diseases.

Data Availability

The [DATA TYPE] data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare no competing interests.

Authors’ Contributions

Xu Chu and Longlong Li contributed equally to this work.

Acknowledgments

This project was supported by the China Postdoctoral Science Foundation (No. 2021M691617) and Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).

References

[1] K. Pafili and M. Roden, “Nonalcoholic Fatty Liver Disease (NAFLD) from Pathogenesis to Treatment Concepts in Humans,” Molecular Metabolism, vol. 50, article 101122, 2021.
[2] T. G. Cotter and M. Rinella, “Nonalcoholic fatty liver disease 2020: the state of the disease,” Gastroenterology, vol. 158, no. 7, pp. 1851–1864, 2020.
[3] S. L. Friedman, B. A. Neuschwander-Tetri, M. Rinella, and A. J. Sanyal, “Mechanisms of NAFLD development and therapeutic strategies,” Nature Medicine, vol. 24, no. 7, pp. 908–922, 2018.
[4] Z. M. Younossi, L. Henry, H. Bush, and A. Mishra, “Clinical and economic burden of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis,” Clinics in Liver Disease, vol. 22, no. 1, pp. 1–10, 2018.
[5] S. Ballestri, S. Zona, G. Targher et al., “Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis,” Journal of Gastroenterology and Hepatology (Australia), vol. 31, no. 5, pp. 936–944, 2016.
[6] G. Targher, C. D. Byrne, A. Lonardo, G. Zoppini, and C. Barbui, “Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis,” Journal of Hepatology, vol. 65, no. 3, pp. 589–600, 2016.
[7] Z. Younossi, “Non-alcoholic fatty liver disease - A global public health perspective,” Journal of Hepatology, vol. 70, no. 3, pp. 531–544, 2019.
[8] A. Kobayashi, M.-I. Kang, Y. Watai et al., “Oxidative and electrophilic stresses activate Nrf2 through inhibition of ubiquitination activity of Keap1,” Microbiology, vol. 26, no. 1, pp. 221–229, 2006.
[9] I. Bellezza, I. Giambaranco, A. Minelli, and R. Donato, “Nrf2-Keap1 signaling in oxidative and reductive stress,” Biochimica et Biophysica Acta-Molecular Cell Research, vol. 1865, no. 5, pp. 721–733, 2018.
[10] D. N. GM, F. A. Karreth, T. J. Humpton et al., “Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis,” Nature, vol. 475, no. 7354, pp. 106–109, 2011.
[11] T. Nguyen, P. Nioi, and C. B. Pickett, “The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress,“ Journal of Biological Chemistry, vol. 284, no. 20, pp. 13291–13295, 2009.
[12] M. Y. Li, X. L. Zhu, B. X. Zhao et al., “Adrenomedullin alleviates the pyroptosis of Leydig cells by promoting autophagy via the ROS-AMPK-mTOR axis,” Cell Death and Disease, vol. 10, no. 7, 2019.
[13] E. C. Hinchy, A. V. Gruszczyk, R. Willows et al., “Mitochondria-derived ROS activate AMP-activated protein kinase (AMPK) indirectly,” Journal of Biological Chemistry, vol. 293, no. 44, pp. 17208–17217, 2018.
[14] E. L. Mills, B. Kelly, A. Logan et al., “Succinate dehydrogenase supports metabolic repurposing of mitochondria to drive inflammatory macrophages,” Cell, vol. 167, no. 2, pp. 457–470.e13, 2016.
[15] H. Shimano and R. Sato, “SREBP-regulated lipid metabolism: convergent physiology – divergent pathophysiology,” Nature Reviews Endocrinology, vol. 13, no. 12, pp. 710–730, 2017.
[16] K.-H. Kim, “Regulation of mammalian acetyl-coenzyme A carboxylase,” Annual Review of Nutrition, vol. 17, no. 1, pp. 77–99, 1997.
[17] E. L. Mills, D. G. Ryan, H. A. Prag et al., “Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1,” Nature, vol. 556, no. 7699, pp. 113–117, 2018.
[18] D. Olgani, E. Farahani, J. Thyristed et al., “SARS-CoV2-mediated suppression of Nrf2-signaling reveals potent anti-viral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate,” Nature Communications, vol. 11, no. 1 article 4938, 2019.
[19] Z. Yi, M. Deng, M. J. Scott et al., “Immune-responsive gene 1/itaconate activates nuclear factor erythroid 2–related factor 2 in hepatocytes to protect against liver ischemia–reperfusion injury,” Hepatology, vol. 72, no. 4, pp. 1394–1411, 2020.
[20] Y. Zheng, Z. Chen, C. She et al., “Four-octyl itaconate activates Nrf2 cascade to protect osteoblasts from hydrogen peroxide-induced oxidative injury,” Nature, vol. 11, no. 9, pp. 772, 2020.
[21] S. T. Liao, C. Han, D. Q. Xu, X. W. Fu, J. S. Wang, and L. Y. Kong, “4-Octyl Itaconate Inhibits Aerobic Glycolysis by
Targeting GAPDH to Exert Anti-Inflammatory Effects,” *Nature Communications*, vol. 10, no. 1, article 5091, 2019.

[22] M. Bambouskova, L. Gorvel, V. Lampropoulou et al., “Electro-philic properties of itaconate and derivatives regulate the IskB-ATF3 inflammatory axis,” *Nature*, vol. 556, no. 7702, pp. 501–504, 2018.

[23] H. Liu, Y. Feng, M. Xu, J. Yang, Z. Wang, and G. di, “Four-Octyl Itonate Activates Keap1-Nrf2 Signaling to Protect Neuronal Cells from Hydrogen Peroxide,” *Cell Communication and Signaling*, vol. 16, no. 1, 2018.

[24] W. He, A. Heinz, D. Jahn, and K. Hiller, “Complexity of macrophage metabolism in infection,” *Current Opinion in Biotechnology*, vol. 68, pp. 231–239, 2021.

[25] J. Henderson, S. D. Naidu, A. T. Dinkova-Kostova, S. Przyborski, R. Stratton, and S. O. Reilly, “The Cell-Permeable Derivative of the Immunoregulatory Metabolite Itonate, 4-Octyl Itonate, Is Anti-Fibrotic in Systemic Sclerosis,” *Cells*, vol. 10, no. 8 article 2053, 2013.

[26] J. Cao, M. Lu, W. Yan, L. Li, and H. Ma, “Dehydroepiandrosterone alleviates intestinal inflammatory damage via GPR30-mediated Nrf2 activation and NLRP3 inflammasome inhibition in colitis mice,” *Free Radical Biology and Medicine*, vol. 172, pp. 386–402, 2021.

[27] Y. Li, S. Xu, M. M. Mihaylova et al., “AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice,” *Cell Metabolism*, vol. 13, no. 4, pp. 376–388, 2011.

[28] M. J. Gómez-Lechón, M. T. Donato, A. Martínez-Romero, N. Jiménez, J. V. Castell, and J. E. O’Connor, “A human hepatocellular in vitro model to investigate steatosis,” *Chemico-Biological Interactions*, vol. 165, no. 2, pp. 106–116, 2007.

[29] J. Araya, R. Rodrigo, L. A. Videla et al., “Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease,” *Clinical Science*, vol. 106, no. 6, pp. 635–643, 2004.

[30] N. Pietrzyk, M. Zakłos-Szyda, M. Koziołkiewicz, and A. Podaśek, “Viburnum opulus L. fruit phenolic compounds protect against FFA-induced steatosis of HepG2 cells via AMPK pathway,” *Journal of Functional Foods*, vol. 80, article 104437, 2021.

[31] L. Li, X. Chu, Y. Yao, J. Cao, Q. Li, and H. Ma, “(-)-hydroxycitric acid alleviates oleic acid-induced steatosis, oxidative stress, and inflammation in primary chicken hepatocytes by regulating amp-activated protein kinase-mediated reactive oxygen species levels,” *Journal of Agricultural and Food Chemistry*, vol. 68, no. 40, pp. 11229–11241, 2020.

[32] A. S. Mutlu, J. Duffy, and M. C. Wang, “Lipid metabolism and lipid signals in aging and longevity,” *Developmental Cell*, vol. 56, no. 10, pp. 1394–1407, 2021.

[33] M. Krssak, A. Brehm, E. Bernroider et al., “Alterations in Post-prandial Hepatic Glycogen Metabolism in Type 2 Diabetes,” *Cell Metabolism*, vol. 53, no. 12, pp. 3048–3056, 2004.

[34] Y. X. Li, T. T. Han, Y. Liu et al., “Insulin resistance caused by lipotoxicity is related to oxidative stress and endoplasmic reticulum stress in LPL gene knockout heterozygous mice,” *Atherosclerosis*, vol. 239, no. 1, pp. 276–282, 2015.

[35] A. Mehlem, C. E. Hagberg, L. Muhl, U. Eriksson, and A. Falkevall, “Imaging of neutral lipids by oil red O for analyzing the metabolic status in health and disease,” *Nature Protocols*, vol. 8, no. 6, pp. 1149–1154, 2013.

[36] W. Zhang, J. Y. Li, X. C. Wei et al., “Effects of dibutyl phthalate on lipid metabolism in liver and hepatocytes based on PPARs/SREBP-1c/FAS/GPAT/AMPK signal pathway,” *Food and Chemical Toxicology*, vol. 149, article 112029, 2021.

[37] M. Hunkele, A. Hagmann, E. Stuttfeld et al., “Structural basis for regulation of human acetyl-CoA carboxylase,” *Nature*, vol. 558, no. 7710, pp. 470–474, 2018.

[38] S. Lepropre, S. Kautbally, M. Octave et al., “AMPK-ACC signaling modulates platelet phospholipids and potentiates thrombus formation,” *Blood*, vol. 132, no. 11, pp. 1180–1192, 2018.

[39] K. Fang, F. Wu, G. Chen et al., “Diosgenin ameliorates palmitic acid-induced lipid accumulation via AMPK/ACC/CPT-1A and SREBP-1c/FAS signaling pathways in LO2 cells,” *BMC Complementary and Alternative Medicine*, vol. 19, no. 1, p. 255, 2019.

[40] W. Shao and P. J. Espenshade, “Expanding roles for SREBP in metabolism,” *Cell Metabolism*, vol. 16, no. 4, pp. 414–419, 2012.

[41] H. Shimano, “SREBPs: novel aspects of SREBPs in the regulation of lipid synthesis,” *FEBS Journal*, vol. 276, no. 3, p. 615, 2009.

[42] C. W. Kim, Y. A. Moon, S. W. Park, D. Cheng, H. J. Kwon, and J. D. Horton, “Induced polymerization of mammalian acetyl-CoA carboxylase by MIG12 provides a tertiary level of regulation of fatty acid synthesis,” *Proceedings of the National Academy of Sciences*, vol. 107, no. 21, pp. 9626–9631, 2010.

[43] S. J. Forrester, D. S. Kikuchi, M. S. Hernandes, Q. Xu, and K. K. Griendling, “Reactive oxygen species in metabolic and inflammatory signaling,” *Circulation Research*, vol. 122, no. 6, pp. 877–902, 2018.

[44] B. J. Berry, A. J. Trewin, A. M. Amitrano, M. Kim, and A. P. Wojtovich, “Use the protonmotive force: mitochondrial uncoupling and reactive oxygen species,” *Journal of Molecular Biology*, vol. 430, no. 21, pp. 3873–3891, 2018.

[45] P. F. Schuck, G. da Costa Ferreira, E. B. Tahara, F. Klamt, A. J. Kowaltowski, and M. Wajner, “cis-4-decenolic acid provokes mitochondrial bienergetic dysfunction in rat brain,” *Life Sciences*, vol. 87, no. 5–6, pp. 139–146, 2010.

[46] M. Wajner and A. U. Amaral, “Mitochondrial dysfunction in fatty acid oxidation disorders: insights from human and animal studies,” *Biochimica Biophysica Acta*, vol. 1840, no. 6, pp. R453–R462, 2014.

[47] J. Zhang, X. Wang, V. Vikash et al., “ROS and ROS-Mediated Cellular Signaling,” *Oxidative Medicine and Cellular Longevity*, vol. 2016, Article ID 4350965, 18 pages, 2016.

[48] G. S. Shadel and T. L. Horvath, “Mitochondrial ROS Signaling in Organismal Homeostasis,” *Cell*, vol. 163, no. 3, pp. 560–569, 2015.

[49] D. Tsikas, “Assessment of lipid peroxidation by measuring malondialdehyde (MDA) and relatives in biological samples: Analytical and biological challenges,” *Analytical Biochemistry*, vol. 524, pp. 13–30, 2017.

[50] M. Schieber and N. S. Chandel, “ROS function in redox signaling and oxidative stress,” *Current Biology*, vol. 24, no. 10, pp. R453–R462, 2014.

[51] S. Singh, S. Vrishni, B. K. Singh, I. Rahman, and P. Kakkar, “Nrf2-ARE stress response mechanism: a control point in oxidative stress-mediated dysfunctions and chronic inflammatory diseases,” *Free Radical Research*, vol. 44, no. 11, pp. 1267–1288, 2010.
[52] C. Yu and J. H. Xiao, “The Keap1-Nrf2 system: a mediator between oxidative stress and aging,” *Oxidative Medicine and Cellular Longevity*, vol. 2021, Article ID 6635460, p. 16, 2021.

[53] M. Maryanovich and A. Gross, “A ROS rheostat for cell fate regulation,” *Trends in Cell Biology*, vol. 23, no. 3, pp. 129–134, 2013.

[54] D. B. Zorov, M. Juhaszova, and S. J. Sollott, “Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release,” *Physiological Reviews*, vol. 94, no. 3, pp. 909–950, 2014.

[55] S. I. Zandalinas and R. Mittler, “ROS-induced ROS release in plant and animal cells,” *Free Radical Biology and Medicine*, vol. 122, pp. 21–27, 2018.

[56] P. Prasun, “Mitochondrial dysfunction in metabolic syndrome,” *Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease*, vol. 1866, no. 10, article 165838, 2020.